ERAS · Erasca, Inc.
Erasca Inc (ERAS)
What's happening
- ERAS is down 0.43% today, trading at $16.31. — Live quote
- Volume today (1,841) is well below its 3-month average of 5,667,840. (Finnhub fundamentals)
- Last quarter's EPS missed estimates: $-0.14 actual vs. $-0.10 estimated (-34.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Aggregate ratings for 2026-09-01 (17 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
Earnings Trends (Quarterly EPS Actual vs Estimate)
Valuation Measures & Ratios
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $5.78B | $4.94B | $609.5M | $359.9M | $384.3M |
| P/E | -19.78 | -17.73 | -4.81 | -2.26 | -2.40 |
| Price/Book | 15.96 | 12.56 | 1.75 | 0.97 | 0.96 |
| EV/EBITDA | -18.78 | -16.70 | -3.79 | — | — |
| ROE | -80.69% | -70.87% | -36.41% | -42.78% | -40.15% |
| ROA | -67.12% | -60.47% | -30.13% | -35.75% | -34.03% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E and PEG aren't shown here — both need historical analyst-consensus estimates, which no free source provides; see the current-period figures above instead.
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-08-14. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Signals describe daily price patterns—not the company’s value and not a recommendation to buy or sell. Read several together; no single indicator predicts what happens next. “Overbought” and “oversold” are conditions, not promises of a reversal.
Indicators None active
Free IEX historical data only goes back to ~2021 — 5Y/Full show whatever's actually available, not a promise of that much history. Indicators are computed client-side from these same price bars; earnings markers ("E") come from Finnhub's free tier (~last 4 quarters + next upcoming) — older quarters aren't available. The move-highlight dots are a heuristic (|% change| vs rolling volatility) with a best-effort headline lookup, not a claim of causation.
Peer and sector context
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Trailing 52-week price return is +947.5%. Finnhub market metrics ↗
Potential concerns
- Latest SEC filing is Form 8-K, filed 2026-08-24; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on ERAS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$47.6M | -$187.9M | -$34.5M | -$38.1M | -$35.6M | -$37.2M | -$67.8M | -$38.9M |
| Net income | -$44.1M | -$183.4M | -$30.6M | -$33.9M | -$31.0M | -$31.2M | -$63.2M | -$35.0M |
| EPS (diluted) | $-0.14 | $-0.60 | $-0.11 | $-0.12 | $-0.11 | $-0.11 | $-0.29 | $-0.23 |
| EPS (basic) | $-0.14 | $-0.60 | $-0.11 | $-0.12 | $-0.11 | $-0.11 | $-0.29 | $-0.23 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $435.1M | $461.2M | $396.2M | $420.4M | $445.4M | $471.2M | $502.5M | $528.9M |
| Total liabilities | $73.2M | $67.7M | $71.0M | $72.5M | $73.1M | $71.7M | $79.0M | $78.9M |
| Stockholders' equity | $361.9M | $393.5M | $325.2M | $347.9M | $372.3M | $399.5M | $423.5M | $450.0M |
| Total current assets | $278.4M | $253.8M | $286.2M | $299.9M | $310.7M | $314.6M | $308.8M | $330.2M |
| Total current liabilities | $33.6M | $26.7M | $28.5M | $28.7M | $28.2M | $25.5M | $31.4M | $30.0M |
| Cash & equivalents | $42.5M | $47.3M | $73.8M | $70.2M | $66.1M | $70.5M | $67.7M | $68.9M |
| Marketable securities (current) | $226.2M | $196.5M | $202.3M | $218.2M | $234.5M | $234.1M | $230.6M | $250.0M |
| Marketable securities (non-current) | $115.5M | $164.7M | $65.7M | $74.0M | $86.1M | $106.5M | $142.2M | $144.4M |
| Property, plant & equipment | $11.9M | $12.6M | $13.3M | $14.0M | $14.8M | $15.6M | $16.3M | $17.2M |
| Other non-current assets | $1.3M | $1.4M | $1.5M | $2.0M | $2.6M | $2.6M | $2.6M | $3.9M |
| Accounts payable | $2.0M | $2.2M | $981.0K | $3.0M | $1.7M | $2.3M | $468.0K | $2.4M |
| Other non-current liabilities | $341.0K | $340.0K | $399.0K | $395.0K | $263.0K | $251.0K | $362.0K | $340.0K |
| Common stock & paid-in capital | $31.0K | $31.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K | $28.0K |
| Retained earnings | -$1.12B | -$1.08B | -$892.2M | -$863.1M | -$832.5M | -$798.6M | -$767.7M | -$735.4M |
| Accumulated other comprehensive income (loss) | -$1.2M | -$699.0K | $628.0K | $649.0K | $415.0K | $628.0K | $405.0K | $1.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$27.3M | -$27.4M | -$21.7M | -$21.7M | -$20.5M | -$31.6M | -$24.6M | -$22.4M |
| Investing cash flow | $19.5M | -$243.8M | $24.7M | $25.7M | $15.7M | $34.3M | $22.6M | -$102.6M |
| Financing cash flow | $3.1M | $244.7M | $575.0K | $41.0K | $447.0K | $33.0K | $801.0K | $21.1M |
| Free cash flow | -$27.3M | -$27.4M | -$21.7M | -$21.7M | -$20.6M | -$31.6M | -$24.6M | -$22.4M |
| Capital expenditures | $8.0K | $36.0K | $9.0K | $6.0K | $30.0K | $83.0K | $0 | $5.0K |
| Depreciation & amortization | $716.0K | $723.0K | $2.3M | $755.0K | $787.0K | $822.0K | $2.8M | $842.0K |
| Share-based compensation | $9.6M | $8.5M | $5.8M | $6.0M | $6.4M | $6.7M | $6.3M | $6.6M |
| Change in accounts payable | -$212.0K | $1.2M | -$2.0M | $1.4M | -$599.0K | $1.8M | -$1.9M | $482.0K |
| Purchases of investments | $0 | $253.2M | $42.2M | $41.5M | $56.6M | $10.7M | $67.1M | $191.8M |
| Sales/maturities of investments | $0 | $100.8M | — | — | — | — | — | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$140.9M | -$179.6M | -$141.5M | -$247.4M | -$124.9M |
| Net income | -$124.5M | -$161.7M | -$125.0M | -$242.8M | -$122.8M |
| EPS (diluted) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
| EPS (basic) | $-0.44 | $-0.69 | $-0.83 | $-1.99 | $-1.85 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $396.2M | $502.5M | $395.3M | $514.9M | $501.4M |
| Total liabilities | $71.0M | $79.0M | $78.6M | $103.1M | $44.9M |
| Stockholders' equity | $325.2M | $423.5M | $316.7M | $411.9M | $456.5M |
| Total current assets | $286.2M | $308.8M | $320.7M | $444.5M | $420.0M |
| Total current liabilities | $28.5M | $31.4M | $26.2M | $48.7M | $26.2M |
| Cash & equivalents | $73.8M | $67.7M | $93.1M | $284.2M | $360.5M |
| Marketable securities (current) | $202.3M | $230.6M | $219.3M | $151.4M | $54.0M |
| Marketable securities (non-current) | $65.7M | $142.2M | $9.6M | — | $44.8M |
| Property, plant & equipment | $13.3M | $16.3M | $22.3M | $24.8M | $16.0M |
| Other non-current assets | $1.5M | $2.6M | $4.4M | $4.8M | $2.9M |
| Accounts payable | $981.0K | $468.0K | $2.0M | $23.0M | $4.7M |
| Other non-current liabilities | $399.0K | $362.0K | $566.0K | $573.0K | $158.0K |
| Common stock & paid-in capital | $28.0K | $28.0K | $15.0K | $15.0K | $12.0K |
| Retained earnings | -$892.2M | -$767.7M | -$606.0M | -$481.0M | -$238.2M |
| Accumulated other comprehensive income (loss) | $628.0K | $405.0K | $77.0K | -$1.0M | -$162.0K |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$95.5M | -$109.4M | -$101.2M | -$103.3M | -$79.6M |
| Investing cash flow | $100.4M | -$156.6M | -$91.2M | -$71.1M | -$64.6M |
| Financing cash flow | $1.1M | $240.7M | $1.3M | $98.1M | $439.4M |
| Free cash flow | -$95.6M | -$109.5M | -$103.0M | -$117.8M | -$90.8M |
| Capital expenditures | $128.0K | $60.0K | $1.8M | $14.6M | $11.2M |
| Depreciation & amortization | $3.1M | $3.8M | $3.7M | $2.6M | $829.0K |
| Share-based compensation | $24.9M | $27.0M | $26.2M | $20.1M | $8.3M |
| Change in accounts payable | $513.0K | -$1.5M | -$886.0K | $676.0K | $1.3M |
| Purchases of investments | $151.0M | $403.2M | $314.4M | $132.3M | $105.8M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding ERAS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Source: Business Quant SEC Form 13F · report period 2026-06-30 · 31 filers
| Filer | Shares | Value | % Out | Qtr Change | Filed |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 24,975,188 | $457.5M | 8.02% | +1.2% | 2026-08-14 |
| T. Rowe Price Investment Management, Inc. | 21,185,839 | $388.1K | 6.80% | -0.3% | 2026-08-14 |
| BlackRock, Inc. | 21,154,146 | $387.5M | 6.79% | +5.0% | 2026-08-07 |
| RTW INVESTMENTS, LP | 17,946,754 | $328.8M | 5.76% | +11.1% | 2026-08-14 |
| Venrock Adviser, LLC | 17,891,812 | $327.8M | 5.75% | +9.2% | 2026-08-14 |
| State Street Corp | 12,184,555 | $223.2M | 3.91% | +31.0% | 2026-08-07 |
| Logos Global Management LP | 12,150,000 | $222.6M | 3.90% | +9.0% | 2026-08-14 |
| VANGUARD CAPITAL MANAGEMENT LLC | 11,402,199 | $208.9M | 3.66% | +1.4% | 2026-06-30 |
| Siren, L.L.C. | 11,397,781 | $208.8M | 3.66% | +1.4% | 2026-08-13 |
| Paradigm Biocapital Advisors LP | 9,550,000 | $175.0M | 3.07% | -8.1% | 2026-08-14 |
| ARCH Venture Management, LLC | 7,091,557 | $129.9M | 2.28% | +0.0% | 2026-08-14 |
| GEODE CAPITAL MANAGEMENT, LLC | 6,501,426 | $119.1M | 2.09% | +8.4% | 2026-08-12 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 6,272,508 | $114.9K | 2.01% | +245.5% | 2026-08-14 |
| Cormorant Asset Management, LP | 6,000,000 | $109.9M | 1.93% | +3.4% | 2026-08-14 |
| Affinity Asset Advisors, LLC | 5,250,000 | $96.2M | 1.69% | -1.9% | 2026-08-13 |
| Vivo Capital, LLC | 4,127,412 | $75.6M | 1.33% | -66.0% | 2026-08-14 |
| ALLIANCEBERNSTEIN L.P. | 4,118,614 | $66.6M | 1.32% | +55.7% | 2026-08-14 |
| Goldman Sachs Group Inc | 3,822,113 | $70.0M | 1.23% | -21.6% | 2026-08-14 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 3,229,321 | $176.3K | 1.04% | +1479.5% | 2026-08-21 |
| Bank Of America Corp /De/ | 3,048,737 | $55.9M | 0.98% | -0.2% | 2026-08-14 |
| FMR LLC | 2,883,417 | $52.8M | 0.93% | +93.5% | 2026-08-13 |
| a16z Capital Management, L.L.C. | 2,862,500 | $52.4M | 0.92% | +0.0% | 2026-08-14 |
| Woodline Partners LP | 2,831,867 | $51.9M | 0.91% | +0.0% | 2026-08-14 |
| JENNISON ASSOCIATES LLC | 2,788,412 | $51.1M | 0.90% | +0.0% | 2026-08-03 |
| Soleus Capital Management, L.P. | 2,700,000 | $49.5M | 0.87% | +0.0% | 2026-08-11 |
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2025-12-15 to 2026-04-01
Recent transactions
- Insiders have net sold 100,000 shares over the last 182 days, across 0 purchases and 2 sales.
- Most recent: Garner Ebun (Chief Legal Officer) — Option exercise of 80,000 shares on 2026-04-01.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Garner Ebun | Chief Legal Officer | Option exercise | 2026-04-01 | 80,000 |
| Morris Shannon | Chief Medical Officer | Option exercise | 2026-03-04 | 20,000 |
| Chacko David M. | CFO and CBO | Other acquisition/disposition | 2025-12-15 | 17,793 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-04-01 | Garner Ebun | Chief Legal Officer | Option exercise | 80,000 | $1.70 |
| 2026-04-01 | Garner Ebun | Chief Legal Officer | Open market sale | 80,000 | $16.40 |
| 2026-03-04 | Morris Shannon | Chief Medical Officer | Option exercise | 20,000 | $1.70 |
| 2026-03-04 | Morris Shannon | Chief Medical Officer | Open market sale | 20,000 | $15.04 |
| 2026-01-07 | Garner Ebun | General Counsel & Corp. Sec. | Option exercise | 120,000 | $1.70 |
| 2026-01-07 | Garner Ebun | General Counsel & Corp. Sec. | Open market sale | 120,000 | $5.59 |
| 2025-12-15 | Chacko David M. | CFO and CBO | Other acquisition/disposition | 17,793 | $1.19 |
| 2025-12-15 | Garner Ebun | General Counsel & Corp. Sec. | Grant / award | 3,902 | $1.19 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-09-03 13:43 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-08-24 | 8-K | 2026-08-24 | View on SEC.gov → |
| 2026-08-12 | 4 | 2026-08-10 | View on SEC.gov → |
| 2026-08-11 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-11 | 8-K | 2026-08-11 | View on SEC.gov → |
| 2026-08-10 | 8-K | 2026-08-10 | View on SEC.gov → |
| 2026-07-14 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-13 | 8-K | 2026-07-13 | View on SEC.gov → |
| 2026-07-01 | 8-K | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
| 2026-06-29 | 4 | 2026-06-26 | View on SEC.gov → |
Recent news
Headlines about ERAS (Erasca, Inc.). Links open the publisher — we don’t host full articles.
-
Attention Long-Term Shareholders of Erasca, Inc. (NASDAQ:
GlobeNewswire · 2026-09-03 -
Long-Term Shareholders of Erasca, Inc. (ERAS) Are Encouraged to Contact Johnson Fistel Regarding Potential Claims
GlobeNewswire · 2026-09-02 -
Trisha Paytas – The Eras of Trish Tour – March 2027
sheldonangmedia.com · 2026-09-01 -
Erasca Inc. (ERAS) Shares Tumble 7.5% to $18.03 as Selling Pressure Mounts - Vanna Flow
vinanet.vn · 2026-08-30 -
Erasca Stock Sinks As Rival Cancer Drug Wins
tipranks.com · 2026-08-28 -
Alger Mid Cap 40 ETF Q2 2026 Portfolio Review
SeekingAlpha · 2026-08-25 -
Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma
Yahoo Finance · 2026-08-24 -
Erasca GAAP EPS of -$0.14
Seeking Alpha · 2026-08-11
No headlines in this category right now — try “All”.